With Novo axing monlunabant, Corbus has a chance to establish CRB-913 as the frontrunner in the CB1 race. The phase 1b data ...

Cellectis is also switching over to in vivo, channelling its resources to two preclinical candidates: HEAL-101, an in vivo ...

Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations. | Eli Lilly has put the kibosh on an early-stage obesity drug after ...

Electra Therapeutics is hoping to raise up to $341.9 million in a surge of IPO funding to power the clinical development of its inflammatory disorder drug ipsoprubart. | Electra Therapeutics is hoping ...

BioNTech has linked gotistobart to median overall survival (OS) of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate (ADC). The small cell lung cancer (SCLC) trial hit its primary endpoint, although the B7-H3-dire ...

Cullinan Therapeutics and Taiho Oncology have unveiled phase 3 data for their tyrosine kinase inhibitor (TKI) that could challenge Johnson & Johnson’s Rybrevant for patients with advanced non-small ...

GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting ...

The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor zanzalintinib in combination with Roche’s ...

GE HealthCare is said to be on the cusp of buying out radiopharmaceutical developer Sofie Biosciences, according to a report by the Financial Times. | GE HealthCare is said to be on the cusp of buying ...